Pharmacology of erectile dysfunction in man.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Pharmacology and Therapeutics

• Publication date

  2006-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.PHARMTHERA.2005.10.011PMID 16443277
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An update on cyclic nucleotide phosphodiesterase (PDE) inhibitors: phosphodiesterases and drug selectivity.

  2005cited by this paper
• Heart disease risk factors predict erectile dysfunction 25 years later: the Rancho Bernardo Study.

  2005cited by this paper
• Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk.

  2005cited by this paper
• Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire.

  2005cited by this paper
• Nitric oxide and penile erectile function.

  2005cited by this paper
• Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development

  2005cited by this paper
• Transient global amnesia after intake of tadalafil, a PDE-5 inhibitor: a possible association?

  2005cited by this paper
• Effect of Tadalafil on Cytochrome P450 3A4–mediated Clearance: Studies in Vitro and in Vivo

  2005cited by this paper
• Male sexuality with advancing age.

  2004cited by this paper
• Prevalence and risk factors of erectile dysfunction in Japanese men with type 2 diabetes.

  2004cited by this paper
• Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men.

  2004cited by this paper
• Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial.

  2004cited by this paper
• Effect of life-style factors on incidence of erectile dysfunction

  2004cited by this paper
• Caveolae and Caveolins in the Cardiovascular System

  2004cited by this paper
• Erectile dysfunction and cardiovascular disease.

  2004cited by this paper
• The efficacy and safety of tadalafil: an update

  2004cited by this paper
• RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: A mechanism for diabetes-associated erectile dysfunction

  2004cited by this paper
• Ten-year incidence of self-reported erectile dysfunction in people with long-term type 1 diabetes.

  2004cited by this paper
• Evaluation of vardenafil and sildenafil on cardiac repolarization.

  2004cited by this paper
• Lower urinary tract symptoms (LUTS) and sexual function in both sexes.

  2004cited by this paper
• Should erectile dysfunction be considered as a marker for acute myocardial infarction? Results from a retrospective cohort study

  2004cited by this paper
• Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial.

  2004cited by this paper
• Earliest time to onset of action leading to successful intercourse with vardenafil determined in an at-home setting: a randomized, double-blind, placebo-controlled trial.

  2004cited by this paper
• Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials

  2004cited by this paper
• Heart disease risk factors predict erectile dysfunction 25 years later (the Rancho Bernardo Study).

  2004cited by this paper
• Quality of life, mood, and sexual function: a path analytic model of treatment effects in men with erectile dysfunction and depressive symptoms

  2004cited by this paper
• Glu298Asp endothelial nitric oxide synthase polymorphism is a risk factor for erectile dysfunction in the Mexican Mestizo population.

  2004cited by this paper
• Effect of acute in vivo sildenafil citrate and in vitro 8-bromo-cGMP treatments on semen parameters and sperm function.

  2004cited by this paper
• Interactions Between Grapefruit Juice and Cardiovascular Drugs

  2004cited by this paper
• Effect of High‐Fat Breakfast and Moderate‐Fat Evening Meal on the Pharmacokinetics of Vardenafil, an Oral Phosphodiesterase‐5 Inhibitor for the Treatment of Erectile Dysfunction

  2003cited by this paper
• RhoA Expression Is Controlled by Nitric Oxide through cGMP-dependent Protein Kinase Activation*

  2003cited by this paper
• Role of some vasoactive mediators in patients with erectile dysfunction: their relationship with angiotensin-converting enzyme and growth hormone

  2003cited by this paper
• Erectile dysfunction in the elderly: epidemiology, etiology and approaches to treatment.

  2003cited by this paper
• Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms.

  2003cited by this paper
• Gene transfer of endothelial nitric oxide synthase partially restores nitric oxide synthesis and erectile function in streptozotocin diabetic rats.

  2003cited by this paper
• Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules

  2003cited by this paper
• Functional prostaglandin E (EP) receptors in human penile corpus cavernosum

  2003cited by this paper
• Regulation of Nitric Oxide–Sensitive Guanylyl Cyclase Cyclic GMP Phosphodiesterases and Regulation of Smooth Muscle Function Structure, Regulation, and Function of Membrane Guanylyl Cyclase Receptors, With a Focus on GC-A Cyclic GMP–Dependent Protein Kinases and the Cardiovascular System: Insights F

  2003cited by this paper
• Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men

  2003cited by this paper
• Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm.

  2003cited by this paper
• Relaxing effects induced by the soluble guanylyl cyclase stimulator BAY 41-2272 in human and rabbit corpus cavernosum.

  2003cited by this paper
• Genetic Risk Factors for Erectile Dysfunction and Genetic Determinants of Drug Response – on the Way to Improve Drug Safety?

  2003cited by this paper
• CLINICAL TRIALS OF SILDENAFIL CITRATE (VIAGRA®) DEMONSTRATE NO INCREASE IN RISK OF MYOCARDIAL INFARCTION AND CARDIOVASCULAR DEATH COMPARED WITH PLACEBO

  2003cited by this paper
• The function of sildenafil on female sexual pathways: a double-blind, cross-over, placebo-controlled study.

  2003cited by this paper
• Expression of guanylyl cyclase B in the human corpus cavernosum penis and the possible involvement of its ligand C-type natriuretic polypeptide in the induction of penile erection.

  2003cited by this paper
• Effects of hypoxia on endothelin-1 sensitivity in the corpus cavernosum.

  2003cited by this paper
• Effects of sildenafil on retinal blood flow and flicker-induced retinal vasodilatation in healthy subjects.

  2003cited by this paper
• Migraine can be induced by sildenafil without changes in middle cerebral artery diameter.

  2003cited by this paper
• Involvement of beta 3-adrenergic receptor activation via cyclic GMP- but not NO-dependent mechanisms in human corpus cavernosum function.

  2003cited by this paper
• The penis as a barometer of endothelial health.

  2003cited by this paper
• Smoking Activates Rho-Kinase in Smooth Muscle Cells of Forearm Vasculature in Humans

  2003cited by this paper
• ACE gene I/D and NOS3 G894T polymorphisms and response to sildenafil in men with erectile dysfunction.

  2003cited by this paper
• Sildenafil does not improve sexual function in men without erectile dysfunction but does reduce the postorgasmic refractory time

  2003cited by this paper
• Is erectile dysfunction predictive of peripheral vascular disease?

  2003cited by this paper
• Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical "Aging Male" symptoms? Results of the "Cologne Male Survey".

  2003cited by this paper
• Viability and safety of combination drug therapies for erectile dysfunction.

  2003cited by this paper
• Suppression of Coronary Artery Spasm by the Rho-Kinase Inhibitor Fasudil in Patients With Vasospastic Angina

  2002cited by this paper
• The ageing penis

  2002cited by this paper
• Cigarette smoking as risk factor for erectile dysfunction: results from an Italian epidemiological study.

  2002cited by this paper
• Systemic and cavernous plasma levels of vasoactive intestinal polypeptide during sexual arousal in healthy males

  2002cited by this paper
• The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers.

  2002cited by this paper
• The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease.

  2002cited by this paper
• The efficacy of sildenafil citrate (Viagra) in clinical populations: an update.

  2002cited by this paper
• RhoA-mediated Ca2+ Sensitization in Erectile Function*

  2002cited by this paper
• Anti-anginal Effect of Fasudil, a Rho-Kinase Inhibitor, in Patients With Stable Effort Angina: A Multicenter Study

  2002cited by this paper
• Penile Arteries and Erection

  2002cited by this paper
• A 4-year update on the safety of sildenafil citrate (Viagra).

  2002cited by this paper
• The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil.

  2002cited by this paper
• The clinical studies of sildenafil for the ageing male.

  2002cited by this paper
• Regulation of human penile smooth muscle tone byprostanoid receptors

  2002cited by this paper
• The ageing male: demographics and challenges

  2002cited by this paper
• Endothelium-dependency of yohimbine-induced corpus cavernosum relaxation

  2002cited by this paper
• Pilot study of the endothelin-A receptor selective antagonist BMS-193884 for the treatment of erectile dysfunction.

  2002cited by this paper
• Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial.

  2002cited by this paper
• Erratum to: Systemic and cavernous plasma levels of endothelin (1–21) during different penile conditions in healthy males and patients with erectile dysfunction

  2001cited by this paper
• Pharmacology of penile erection.

  2001cited by this paper
• Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough?

  2001cited by this paper
• Sexual Dysfunction in Hypertensive Patients Treated with Losartan

  2001cited by this paper
• Evaluation of oral Ro70-0004/003, an α1A-adrenoceptor antagonist, in the treatment of male erectile dysfunction

  2001cited by this paper
• Assessment of the efficacy and safety of Viagra® (sildenafil citrate) in men with erectile dysfunction during long-term treatment

  2001cited by this paper
• Possible role of bradykinin and angiotensin II in the regulation of penile erection and detumescence.

  2001cited by this paper
• Determination of Human Angiotensin Converting Enzyme (ACE) Gene Polymorphisms in Erectile Dysfunction: Frequency Differences of ACE Gene Polymorphisms according to the Method of Analysis

  2001cited by this paper
• Expression of different phosphodiesterase genes in human cavernous smooth muscle.

  2001cited by this paper
• Comparative evaluation of treatments for erectile dysfunction in patients with prostate cancer after radical retropubic prostatectomy

  2001cited by this paper
• Systemic and cavernosal plasma levels of endothelin (1-21) during different penile conditions in healthy males and patients with erectile dysfunction.

  2001cited by this paper
• Systematic review of randomised controlled trials of sildenafil (Viagra) in the treatment of male erectile dysfunction.

  2001cited by this paper
• Plasma levels of angiotensin II during different penile conditions in the cavernous and systemic blood of healthy men and patients with erectile dysfunction.

  2001cited by this paper
• Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway

  2001cited by this paper
• Does prostaglandin E1 therapy modify the intracavernous musculature?

  2000cited by this paper
• Expression of nitric oxide-sensitive guanylyl cyclase subunits in human corpus cavernosum.

  2000cited by this paper
• Human recombinant soluble guanylyl cyclase: expression, purification, and regulation.

  2000cited by this paper
• Cloning and characterization of two splice variants of human phosphodiesterase 11A.

  2000cited by this paper
• Oral phentolamine: an alpha-1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction

  2000cited by this paper
• Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions.

  2000cited by this paper
• Cigarette Smoking, Hypertension and Erectile Dysfunction

  2000cited by this paper
• Plasma levels of cavernous and systemic norepinephrine and epinephrine in men during different phases of penile erection.

  2000cited by this paper
• Three-year outcome of a progressive treatment program for erectile dysfunction with intracavernous injections of vasoactive drugs.

  2000cited by this paper
• Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A.

  2000cited by this paper
• The role of prostaglandins in penile erection.

  2000cited by this paper
• Erectile dysfunction in the ageing man

  2000cited by this paper

• How sexual behavior in male rats is inhibited by repeated maternal separation during early postnatal development

  2026cites this paper
• Functional, Nutraceutical and Health Endorsing Perspectives of Saffron

  2025cites this paper
• The functions of hydrogen sulfide on the urogenital system of both males and females: from inception to the present

  2024cites this paper
• Analysis of phosphodiesterase type 5 inhibitors and analogues as adulterants in herbal dietary food supplements in Saudi market using green UPLC-MS/MS method: Assessment of the greenness and whiteness profiles

  2024cites this paper
• Potential Effect of the Circadian Clock on Erectile Dysfunction

  2022cites this paper
• A Review on Phosphodiesterase-5 Inhibitors as a Topical Therapy for Erectile Dysfunction.

  2022cites this paper
• Botanical Medicine and Natural Products Used for Erectile Dysfunction.

  2020cites this paper
• Assessment of the efficacy of α-lipoic acid in treatment of diabetes mellitus patients with erectile dysfunction

  2020cites this paper
• Diabetes mellitus and the impairment of male reproductive function: Possible signaling pathways.

  2020cites this paper
• Unani medicines used in the treatment of diabetes induced erectile dysfunction: A review

  2019cites this paper
• Tetracarpidium conophorum Müll. Arg modulates sexual behaviour and biochemical parameters relevant to sexual function in male Wistar rats.

  2019cites this paper
• Stimulators and activators of soluble guanylate cyclase for urogenital disorders

  2018cites this paper
• Therapeutic potential of Mucuna pruriens (Linn.) on ageing induced damage in dorsal nerve of the penis and its implication on erectile function: an experimental study using albino rats

  2018cites this paper
• Expression profiles of eNOS, iNOS and microRNA-27b in the corpus cavernosum of rats submitted to chronic alcoholism and Diabetes mellitus.

  2017cites this paper
• APHRODISIAC ACTIVITY OF ACID PHOS ON MALE ALBINO RAT

  2017cites this paper
• Effect of dietary supplementation of tiger nut (Cyperus esculentus l.) and walnut (Tetracarpidium conophorum müll. Arg.) on sexual behavior, hormonal level, and antioxidant status in male rats

  2017cites this paper
• Phytochemical and Pharmacological Evaluation of Kigelia africana and Cannabis indica for their Aphrodisiac Potential

  2017cites this paper
• A Review on Medicinal Properties of Saffron toward Major Diseases

  2017influential citation
• EFFICACY OF RASON, ASHWAGANDHA AND ASHWATHA IN DIABETIC ERECTILE DYSFUNCTION – A CRITICAL REVIEW

  2017cites this paper
• ERECTILE DYSFUNCTION AND ITS PHARMACOLOGY: AN OVERVIEW

  2017influential citation
• The Role of the Hydrogen Sulfide Pathway in Male and Female Urogenital System in Health and Disease

  2017cites this paper
• Erectile Dysfunction

  2016cites this paper
• The effects of sildenafil after chronic L-NAME administration in male rat sexual behavior.

  2016cites this paper
• Diabetes and Sexual Function

  2016cites this paper
• Influence of chloroform extract of Sida acuta Burm.f. leaves on the Sexual Behavior of normal rats

  2015cites this paper
• Animal models of erectile dysfunction.

  2015cites this paper
• Ameliorative potentials of medicinal plants on the pathophysiological complications of diabetes mellitus: A review

  2015cites this paper
• Effects of quercetin on intracavernous pressure and expression of nitrogen synthase isoforms in arterial erectile dysfunction rat model.

  2015cites this paper
• Evaluation of anti-inflammatory activity of the bark of Eysenhardtia polystachya in experimental animal models

  2015cites this paper
• Gas what: NO is not the only answer to sexual function

  2015cites this paper
• Wearable and wireless measurement system for evaluating penile tumescence

  2015cites this paper
• Hydrogen Sulfide and Urogenital Tract.

  2015cites this paper
• A new therapeutic approach to erectile dysfunction: urotensin-II receptor high affinity agonist ligands

  2014cites this paper
• CALL FOR PAPERS Cardiovascular and Cerebrovascular Aging-New Mechanisms and Insights Oxidative stress associated with middle aging leads to sympathetic hyperactivity and downregulation of soluble guanylyl cyclase in corpus cavernosum

  2014cites this paper
• Magnetic solid-phase extraction based on methylcellulose coated-Fe3O4-SiO2-phenyl for HPLC-DAD analysis of sildenafil and its metabolite in biological samples.

  2014cites this paper
• Prolonged therapy with the soluble guanylyl cyclase activator BAY 60-2770 restores the erectile function in obese mice.

  2014cites this paper
• Surgical Therapy of Erectile Dysfunction in Men with Diabetes Mellitus

  2014cites this paper
• Oxidative stress associated with middle aging leads to sympathetic hyperactivity and downregulation of soluble guanylyl cyclase in corpus cavernosum.

  2014cites this paper
• Cyclic nucleotide signaling and synaptic plasticity

  2014influential citation
• hyperactivity and downregulation of soluble guanylyl cyclase in corpus

  2014cites this paper
• Beyond Erectile Dysfunction: Understanding PDE5 Activity In The Central Nervous System

  2014cites this paper
• Advanced glycation end-products: a common pathway in diabetes and age-related erectile dysfunction

  2013cites this paper
• Nature's Aphrodisiacs - A Review of Current Scientific Literature

  2013cites this paper
• Determination of sildenafil, vardenafil and aildenafil in human plasma by dispersive liquid-liquid microextraction-back extraction based on ionic liquid and high performance liquid chromatography-ultraviolet detection.

  2013cites this paper
• The role of modifiable risk factors in the presence and development of lower urinary tract symptoms (LUTS) and sexual dysfunction in ageing men.

  2013cites this paper
• BPH/LUTS and ED: common pharmacological pathways for a common treatment.

  2013cites this paper
• Potential role of Rho kinase inhibitors in combating diabetes-related complications including diabetic neuropathy--a review.

  2013cites this paper
• Effect of sildenafil-induced nitric oxide on the histomorphology of cardiomyocytes in male rats

  2013cites this paper
• Erectile Dysfunction - Disease-Associated Mechanisms and Novel Insights into Therapy

  2012cites this paper
• Erectile Dysfunction: A Chronic Complication of the Diabetes Mellitus

  2012cites this paper
• Fisiologia peniana e disfunção erétil: uma revisão de literatura Penile Physiology and erectile dysfunction: a review of literature

  2012cites this paper
• Clinical and biopsychosocial determinants of sexual dysfunction in middle-aged and older Australian men.

  2012cites this paper
• Effect of vardenafil on nitric oxide synthase expression in the paraventricular nucleus of rats without sexual stimulation

  2012cites this paper
• Effect of novel synthetic evodiamine analogue on sexual behavior in male rats

  2012cites this paper
• PDEI-5 for erectile dysfunction: a potential role in seizure susceptibility.

  2012cites this paper
• Diabetes-induced erectile dysfunction: epidemiology, pathophysiology and management.

  2011influential citation
• Intravenous sildenafil as a preconditioning drug against hemodynamic consequences of warm ischemia-reperfusion on the kidney.

  2011cites this paper
• Nitric oxide-induced vasorelaxation in response to PnTx2-6 toxin from Phoneutria nigriventer spider in rat cavernosal tissue.

  2010cites this paper
• Phosphodiesterase‐5 inhibitors and rosacea: report of 10 cases

  2009cites this paper
• Sildenafil as a protecting drug for warm ischemic kidney transplants: experimental results.

  2009cites this paper
• Diabetes and Sexual Health

  2009cites this paper
• Precondicionamiento farmacológico con sildenafilo del riñón con isquemia normotérmica

  2008cites this paper
• Expression of the PDE5 enzyme on human retinal tissue: new aspects of PDE5 inhibitors ocular side effects

  2008cites this paper
• [Pharmacological preconditioning with sildenafil of warm ischemic kidneys].

  2008cites this paper
• Endothelial Dysfunction, Erectile Dysfunction and Phosphodiesterase 5 Inhibitors. An Update of the Current Data and Future Perspectives

  2007cites this paper
• Relaxation of the isolated human internal anal sphincter by sildenafil

  2007cites this paper
• Erectile dysfunction

  2006cites this paper
• Dopamine D4 receptors and the regulation of penile erection

  2006cites this paper